These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

663 related articles for article (PubMed ID: 10569942)

  • 1. DNA topoisomerases as targets for the anticancer drug TAS-103: DNA interactions and topoisomerase catalytic inhibition.
    Fortune JM; Velea L; Graves DE; Utsugi T; Yamada Y; Osheroff N
    Biochemistry; 1999 Nov; 38(47):15580-6. PubMed ID: 10569942
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DNA topoisomerases as targets for the anticancer drug TAS-103: primary cellular target and DNA cleavage enhancement.
    Byl JA; Fortune JM; Burden DA; Nitiss JL; Utsugi T; Yamada Y; Osheroff N
    Biochemistry; 1999 Nov; 38(47):15573-9. PubMed ID: 10569941
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antitumor activity of XR5944, a novel and potent topoisomerase poison.
    Stewart AJ; Mistry P; Dangerfield W; Bootle D; Baker M; Kofler B; Okiji S; Baguley BC; Denny WA; Charlton PA
    Anticancer Drugs; 2001 Apr; 12(4):359-67. PubMed ID: 11335793
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DNA topoisomerase II as the target for the anticancer drug TOP-53: mechanistic basis for drug action.
    Byl JA; Cline SD; Utsugi T; Kobunai T; Yamada Y; Osheroff N
    Biochemistry; 2001 Jan; 40(3):712-8. PubMed ID: 11170388
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Establishment and characterization of 6-[[2-(Dimethylamino)ethyl]amino]-3-hydroxy-7H-indeno[2,1-c]quinolin-7-one dihydrochloride (TAS-103)-resistant cell lines.
    Aoyagi Y; Kobunai T; Utsugi T; Wierzba K; Yamada Y
    Jpn J Cancer Res; 2000 May; 91(5):543-50. PubMed ID: 10835500
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An investigation into the formation of N- [2-(dimethylamino)ethyl]acridine-4-carboxamide (DACA) and 6-[2-(dimethylamino)ethylamino]- 3-hydroxy-7H-indeno[2, 1-C]quinolin-7-one dihydrochloride (TAS-103) stabilised DNA topoisomerase I and II cleavable complexes in human leukaemia cells.
    Padget K; Stewart A; Charlton P; Tilby MJ; Austin CA
    Biochem Pharmacol; 2000 Sep; 60(6):817-21. PubMed ID: 10930536
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chinese hamster ovary cells resistant to the topoisomerase II catalytic inhibitor ICRF-159: a Tyr49Phe mutation confers high-level resistance to bisdioxopiperazines.
    Sehested M; Wessel I; Jensen LH; Holm B; Oliveri RS; Kenwrick S; Creighton AM; Nitiss JL; Jensen PB
    Cancer Res; 1998 Apr; 58(7):1460-8. PubMed ID: 9537249
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antitumor activity of a novel quinoline derivative, TAS-103, with inhibitory effects on topoisomerases I and II.
    Utsugi T; Aoyagi K; Asao T; Okazaki S; Aoyagi Y; Sano M; Wierzba K; Yamada Y
    Jpn J Cancer Res; 1997 Oct; 88(10):992-1002. PubMed ID: 9414662
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Covalent attachment of ethidium to DNA results in enhanced topoisomerase II-mediated DNA cleavage.
    Marx G; Zhou H; Graves DE; Osheroff N
    Biochemistry; 1997 Dec; 36(50):15884-91. PubMed ID: 9398321
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanism of action of the dual topoisomerase-I and -II inhibitor TAS-103 and activity against (multi)drug resistant cells.
    Minderman H; Wrzosek C; Cao S; Utsugi T; Kobunai T; Yamada Y; Rustum YM
    Cancer Chemother Pharmacol; 2000; 45(1):78-84. PubMed ID: 10647506
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction of topoisomerase II-mediated DNA cleavage by a protoberberine alkaloid, berberrubine.
    Kim SA; Kwon Y; Kim JH; Muller MT; Chung IK
    Biochemistry; 1998 Nov; 37(46):16316-24. PubMed ID: 9819224
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased sensitivity to quinolone antibacterials can be engineered in human topoisomerase IIalpha by selective mutagenesis.
    Hammonds TR; Foster SR; Maxwell A
    J Mol Biol; 2000 Jul; 300(3):481-91. PubMed ID: 10884345
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The geometry of DNA supercoils modulates topoisomerase-mediated DNA cleavage and enzyme response to anticancer drugs.
    McClendon AK; Osheroff N
    Biochemistry; 2006 Mar; 45(9):3040-50. PubMed ID: 16503659
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acetyl-boswellic acids are novel catalytic inhibitors of human topoisomerases I and IIalpha.
    Syrovets T; Büchele B; Gedig E; Slupsky JR; Simmet T
    Mol Pharmacol; 2000 Jul; 58(1):71-81. PubMed ID: 10860928
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DNA cleavage and religation by human topoisomerase II alpha at high temperature.
    Bromberg KD; Osheroff N
    Biochemistry; 2001 Jul; 40(28):8410-8. PubMed ID: 11444988
    [TBL] [Abstract][Full Text] [Related]  

  • 16. F 11782, a novel epipodophylloid non-intercalating dual catalytic inhibitor of topoisomerases I and II with an original mechanism of action.
    Perrin D; van Hille B; Barret JM; Kruczynski A; Etiévant C; Imbert T; Hill BT
    Biochem Pharmacol; 2000 Apr; 59(7):807-19. PubMed ID: 10718339
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel xanthone-polyamine conjugates as catalytic inhibitors of human topoisomerase IIα.
    Minniti E; Byl JAW; Riccardi L; Sissi C; Rosini M; De Vivo M; Minarini A; Osheroff N
    Bioorg Med Chem Lett; 2017 Oct; 27(20):4687-4693. PubMed ID: 28919339
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and biological evaluation of C1-O-substituted-3-(3-butylamino-2-hydroxy-propoxy)-xanthen-9-one as topoisomerase IIα catalytic inhibitors.
    Park S; Hong E; Kwak SY; Jun KY; Lee ES; Kwon Y; Na Y
    Eur J Med Chem; 2016 Nov; 123():211-225. PubMed ID: 27484510
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Merbarone inhibits the catalytic activity of human topoisomerase IIalpha by blocking DNA cleavage.
    Fortune JM; Osheroff N
    J Biol Chem; 1998 Jul; 273(28):17643-50. PubMed ID: 9651360
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro antitumor activity of TAS-103 against freshly-isolated human colorectal cancer.
    Tsunoda T; Tanimura H; Yamaue H; Ishimoto K; Kobunai T; Yamada Y
    Anticancer Res; 2001; 21(6A):3897-902. PubMed ID: 11911266
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.